Wells Fargo Doesn’t Think Becton Dickinson (BDX) Is Done Skyrocketing
Wells Fargo upgraded Becton Dickinson (BDX) to Overweight, raising its price target to $242. The medical device maker reported Q4 revenue of $5.27B and adjusted EPS of $4.15, with full-year adjusted EPS at $12.70. Wells Fargo cited improved execution and prudent fiscal 2027 guidance.
How this was made

The 30-second read
Why it matters
The upgrade could trigger buying interest and modest price appreciation.
Market read
Analyst upgrade provides a fresh catalyst for BDX, likely supporting short‑term upside.
What to watch
Potential headwinds from regulatory changes or competitive pricing pressure.
Background
Wells Fargo highlighted improved execution and a prudent FY2027 guidance, noting room for upside.
Ticker impact
Wells Fargo upgraded Becton Dickinson to Overweight and raised its price target to $242, indicating fresh analyst optimism.
likely upward pressure as investors price in the new target.
The upgrade is a primary disclosure and provides a concrete catalyst for buying pressure.
Market effects
May lift sentiment in the medical device sector as peers could be re‑rated.
Limited to U.S. markets where BDX trades.
Minor; primarily affects BDX shareholders and sector investors.
Counterpoint
The upgrade may be premature if execution improvements falter.
Key entities
- analystWells Fargo
Upgraded BDX to Overweight and raised price target.




